000282919 001__ 282919
000282919 005__ 20251218103446.0
000282919 0247_ $$2doi$$a10.5281/ZENODO.15748014
000282919 0247_ $$2doi$$a10.5281/zenodo.15748014
000282919 037__ $$aDZNE-2025-01380
000282919 1001_ $$0P:(DE-2719)9001970$$aHampton Leonard$$b0
000282919 245__ $$aDataset: Global Parkinson's Genetics Program Data Release 10, v5
000282919 260__ $$bZenodo$$c2025
000282919 3367_ $$2BibTeX$$aMISC
000282919 3367_ $$0PUB:(DE-HGF)32$$2PUB:(DE-HGF)$$aDataset$$bdataset$$mdataset$$s1765985095_5347
000282919 3367_ $$026$$2EndNote$$aChart or Table
000282919 3367_ $$2DataCite$$aDataset
000282919 3367_ $$2ORCID$$aDATA_SET
000282919 3367_ $$2DINI$$aResearchData
000282919 520__ $$aIn July 2025, GP2 announced the 10th data release on the Terra and the Verily® Workbench platforms in collaboration with AMP® PD. This release includes 11,109 additional genotyped participants and 13,339 additional WGS participants. The genotype array (NBA) data, including locally-restricted samples, now consists of a total of 82,944 genotyped participants (36,939 PD cases, 19,821 Controls, and 26,184 ‘Other’ phenotypes). When removing the locally-restricted samples, these now consist of 65,303 samples (28,586 PD cases, 15,258 Controls, and 21,459 ‘Other’ phenotypes). The whole genome sequencing (WGS) data now consists of a total of 21,073 sequenced participants (8,134 PD cases, 3,531 Controls, and 9,408 ‘Other’ phenotypes). When removing the locally-restricted samples, these now consist of 16,608 participants (6,801 PD cases, 3,244 Controls, and 6,563 ‘Other’ phenotypes). Of note, cases recruited via the Monogenic network are coded as ‘Other’. The clinical exome data now consists of 10,454 samples with PD (Release 8). Of the 92,021 unique samples with genetic data (NBA, WGS, or clinical exome), 26,982 individuals also have additional extended clinical information. Please see the accompanying blog for further description of this release. To obtain data access, please see https://amp-pd.org/researchers/data-use-agreement. For any publications using data from this release, please reference the DOI number and the following statement: 'Data (DOI 10.5281/zenodo.15748014, release 10) and/or code used in the preparation of this article were obtained from Global Parkinson’s Genetics Program (GP2). GP2 is funded by the Aligning Science Across Parkinson’s (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson’s Research (https://gp2.org). For a complete list of GP2 members see https://gp2.org.'
000282919 536__ $$0G:(DE-HGF)POF4-354$$a354 - Disease Prevention and Healthy Aging (POF4-354)$$cPOF4-354$$fPOF IV$$x0
000282919 588__ $$aDataset connected to DataCite
000282919 7001_ $$aMike Nalls$$b1
000282919 7001_ $$aDan Vitale$$b2
000282919 7001_ $$aMathew Koretsky$$b3
000282919 7001_ $$aKristin Levine$$b4
000282919 7001_ $$aMary Makarious$$b5
000282919 7001_ $$0P:(DE-2719)9001362$$aFang, Zih-Hua$$b6$$udzne
000282919 7001_ $$aJones, Lietsel$$b7
000282919 7001_ $$aSolle, J.$$b8
000282919 773__ $$a10.5281/zenodo.15748014
000282919 7870_ $$0DZNE-2024-01334$$aLeonard, Hampton et.al.$$dZenodo, 2023$$iRelatedTo$$r$$tDataset: Global Parkinson's Genetics Program Data Release 5, v1
000282919 909CO $$ooai:pub.dzne.de:282919$$pVDB
000282919 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001362$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000282919 9131_ $$0G:(DE-HGF)POF4-354$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Prevention and Healthy Aging$$x0
000282919 9141_ $$y2025
000282919 9201_ $$0I:(DE-2719)1210002$$kAG Heutink$$lGenome Biology of Neurodegenerative Diseases$$x0
000282919 980__ $$adataset
000282919 980__ $$aVDB
000282919 980__ $$aI:(DE-2719)1210002
000282919 980__ $$aUNRESTRICTED